Vinay Thohan, MD
Advanced Heart Failure and Transplant Cardiology · Asheville, NCNPI 1184650798
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $122,046 of the $164,164 with a category attached, or 74.3%. 26 manufacturers reported payments, led by Boehringer Ingelheim at 44.8% of the total. Reporting peaked in 2022 at $38,260 and has fallen 55.2% since, to $17,139 in 2025.
Across 446 payments — averaging $368.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$74K
- Pfizer$45K
- Impulse Dynamics (USA) Inc.$16K
- Lilly USA, LLC$10K
- Abbott$10K
- E.r. Squibb & Sons, L.L.C.$6K
- plus $5K from 20 others
Across 8 payments — averaging $2867.77 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$23K
What the payments were for
- Consulting fees$15,1339%
- Speaking & faculty fees$122,04674%
- Travel & lodging$13,3908%
- Food & beverage$13,4678%
- Education$1290%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 67 | $73,586 |
| Pfizer | 59 | $45,105 |
| Impulse Dynamics (USA) Inc. | 27 | $15,710 |
| Lilly USA, LLC | 9 | $9,900 |
| Abbott | 152 | $9,552 |
| E.r. Squibb & Sons, L.L.C. | 17 | $5,507 |
| Bayer | 7 | $1,346 |
| Actelion Pharmaceuticals US, Inc. | 26 | $817 |
| Abiomed | 7 | $593 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 25 | $392 |
| Merck | 12 | $311 |
| Medtronic(2 entities) | 2 | $236 |
| AstraZeneca | 10 | $171 |
| Cvrx, Inc. | 2 | $152 |
| Amgen | 3 | $147 |
| Sandoz | 2 | $144 |
| Bridgebio Pharma, Inc. | 4 | $134 |
| United Therapeutics Corporation | 3 | $74 |
| Atricure, Inc. | 3 | $65 |
| Alnylam Pharmaceuticals Inc. | 2 | $47 |
| Novartis | 2 | $44 |
| Cardiovascular Systems Inc. | 1 | $33 |
| Lexicon Pharmaceuticals, Inc. | 1 | $27 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $26 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Novo Nordisk | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$82,561
- VYNDAQEL$44,197
- OPTIMIZER SMART SYSTEM$11,280
- OPTIMIZER$5,074
- CAMZYOS$5,055
- CardioMEMS HF System$4,825
- Adempas$1,131
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$267
- HeartMate Touch$266
- HeartMate 3 Left Ventricular Dev$258
- Impella$236
- CARDIOMEMS$234
- HeartWare HVAD$138
- Barostim Neo System$124
- TREPROSTINIL$115
- NAVITOR$115
- VERQUVO$106
How this compares
$164,164 in reported general payments places this provider in the 80th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.
See all advanced heart failure and transplant cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 172 | $4,019,845 |
| AdempasRiociguat | 101 | $1,364,044 |
| Tyvaso DpiTreprostinil | 37 | $895,786 |
| OpsumitMacitentan | 59 | $744,712 |
| Orenitram ErTreprostinil Diolamine | 49 | $587,449 |
| UptraviSelexipag | 21 | $436,337 |
| JardianceEmpagliflozin | 377 | $393,894 |
| CamzyosMavacamten | 42 | $337,167 |
| EntrestoSacubitril/Valsartan | 258 | $320,280 |
| VyndaqelTafamidis Meglumine | 13 | $290,398 |
| EliquisApixaban | 213 | $201,914 |
| FarxigaDapagliflozin Propanediol | 61 | $62,287 |
| XareltoRivaroxaban | 33 | $35,778 |
| Ambrisentan | 15 | $18,657 |
| Tadalafil | 22 | $12,833 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $45,105 | $4,512,157398 claims |
| BayerAdempas | $1,346 | $1,364,044101 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $817 | $1,181,04980 claims |
| Boehringer IngelheimJardiance | $73,586 | $393,894377 claims |
| E.r. Squibb & Sons, L.L.C.Camzyos | $5,507 | $337,16742 claims |
| NovartisEntresto | $44 | $320,280258 claims |
| AstraZenecaFarxiga | $171 | $62,28761 claims |
| AmgenCorlanor | $147 | $9,83611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 31 advanced heart failure and transplant cardiology providers in North Carolina.
Other advanced heart failure and transplant cardiology in Asheville
- Benjamin TrichonAsheville$37K
- Matthew RiesbeckAsheville$13K
- Daniel BensimhonGreensboro$2.1M
- Stephen GreeneDurham$582K
- John RommelWilmington$263K
- Stephen ZouzoulasConcord$244K
- Hassan AlhosainiWinston Salem$195K
- Kishan ParikhRaleigh$158K
- Emil MissovGreenville$71K
- David IshizawarRaleigh$55K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.